MX2012013206A - Inhibidores de quinasa biciclica fusionada. - Google Patents

Inhibidores de quinasa biciclica fusionada.

Info

Publication number
MX2012013206A
MX2012013206A MX2012013206A MX2012013206A MX2012013206A MX 2012013206 A MX2012013206 A MX 2012013206A MX 2012013206 A MX2012013206 A MX 2012013206A MX 2012013206 A MX2012013206 A MX 2012013206A MX 2012013206 A MX2012013206 A MX 2012013206A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
fused bicyclic
bicyclic kinase
formula
treatment
Prior art date
Application number
MX2012013206A
Other languages
English (en)
Inventor
Andrew Philip Crew
Arno G Steinig
Meizhong Jin
Jing Wang
Andrew Kleinberg
Mark J Mulvihill
An-Hu Li
Original Assignee
Osi Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharmaceuticals Llc filed Critical Osi Pharmaceuticals Llc
Publication of MX2012013206A publication Critical patent/MX2012013206A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de fórmula I, como se muestra abajo y define aquí: (ver Fórmula) sales farmacéuticamente aceptables de los mismos, síntesis, intermedios, formulaciones y métodos de tratamiento de enfermedad, incluyendo el tratamiento de cánceres, tales como tumores impulsados por lo menos en parte por al menos uno de RON, MET o ALK.
MX2012013206A 2010-05-14 2011-05-16 Inhibidores de quinasa biciclica fusionada. MX2012013206A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33473410P 2010-05-14 2010-05-14
PCT/US2011/036572 WO2011143645A1 (en) 2010-05-14 2011-05-16 Fused bicyclic kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2012013206A true MX2012013206A (es) 2012-12-17

Family

ID=44211949

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013206A MX2012013206A (es) 2010-05-14 2011-05-16 Inhibidores de quinasa biciclica fusionada.

Country Status (19)

Country Link
US (2) US8445510B2 (es)
EP (1) EP2569314B1 (es)
JP (1) JP5820472B2 (es)
KR (1) KR20130118213A (es)
CN (1) CN102971316A (es)
AR (1) AR081039A1 (es)
AU (1) AU2011252784A1 (es)
BR (1) BR112012028674A2 (es)
CA (1) CA2790847A1 (es)
EA (1) EA201291246A1 (es)
ES (1) ES2604481T3 (es)
MX (1) MX2012013206A (es)
PH (1) PH12012502102A1 (es)
PL (1) PL2569314T3 (es)
PT (1) PT2569314T (es)
SG (1) SG184822A1 (es)
TW (1) TW201141863A (es)
WO (1) WO2011143645A1 (es)
ZA (1) ZA201208489B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010059771A1 (en) 2008-11-20 2010-05-27 Osi Pharmaceuticals, Inc. Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
MX2013001313A (es) * 2010-08-05 2013-06-13 Amgen Inc Compuestos de bencimidazol y azabencimidazol que inhiben la cinasa del linfoma anaplasico.
EP2710003A1 (en) * 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2867233A1 (en) * 2012-07-03 2015-05-06 Aurigene Discovery Technologies Limited 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
CN105712992B (zh) * 2012-09-29 2018-10-26 上海科州药物研发有限公司 作为cMet抑制剂的化合物及其制备方法和用途
MX2015009270A (es) * 2013-01-18 2015-10-30 Hoffmann La Roche Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
HRP20181392T1 (hr) * 2013-03-15 2018-10-19 Plexxikon Inc. Heterociklični spojevi i njihova uporaba
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
CN104628555B (zh) * 2015-01-05 2016-11-30 烟台蓓丰医药科技有限公司 一种药物中间体4-(4-氯苯基)环己基-1-甲酸的合成方法
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
US20230339937A1 (en) 2020-06-19 2023-10-26 Sato Pharmaceutical Co., Ltd. Condensed ring compounds that inhibit h-pgds
WO2025070690A1 (ja) 2023-09-29 2025-04-03 第一三共株式会社 ３－フェニルプロピルアミン誘導体

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360531A (en) 1981-04-09 1982-11-23 The Upjohn Company Substituted cycloalkanes
US6235769B1 (en) 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
AP2003002929A0 (en) 2001-06-23 2003-12-31 Aventis Pharma Inc Pyrrolopyrimidines as protein kinase inhibitors
TW200301251A (en) 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
KR20040111445A (ko) 2002-03-28 2004-12-31 에자이 가부시키가이샤 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌
DK1569899T3 (da) 2002-12-10 2006-10-23 Wyeth Corp Substituerede 3-alkyl- og 3-arylalkyl-1H-indol-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
RS53118B (sr) 2003-02-26 2014-06-30 Sugen Inc. Aminoheteroaril jedinjenja kao inhibitori protein kinaze
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
JP2007516180A (ja) 2003-07-02 2007-06-21 スゲン，インコーポレイティド ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
PL1696920T3 (pl) 2003-12-19 2015-03-31 Plexxikon Inc Związki i sposoby opracowywania modulatorów Ret
US20050182060A1 (en) 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
BRPI0513899A (pt) 2004-07-27 2008-05-20 Sgx Pharmaceuticals Inc moduladores de cinase heterocìclica de anel fundido
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
WO2006021886A1 (en) 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
ATE492544T1 (de) 2004-08-26 2011-01-15 Pfizer Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
GEP20104906B (en) 2004-08-26 2010-02-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
CA2608733A1 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
MX2007014811A (es) 2005-06-10 2008-02-14 Boehringer Ingelheim Int Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos.
DK2395004T3 (en) 2005-06-22 2016-03-21 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
CA2630884A1 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
JP2009517432A (ja) 2005-11-30 2009-04-30 エフ．ホフマン−ラ ロシュ アーゲー ３−アミノ−２−アリールプロピルアザインドールおよびその使用
KR101146852B1 (ko) 2005-12-05 2012-05-16 화이자 프로덕츠 인크. Ｃ?ｍｅｔ／ｈｇｆｒ 억제제의 다형체
WO2007067537A1 (en) 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
HUE030390T2 (en) 2005-12-21 2017-05-29 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
EP2032578A2 (en) 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
EP2057125B1 (en) 2006-08-16 2011-03-30 F. Hoffmann-La Roche AG Non-nucleoside reverse transcriptase inhibitors
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
US8639558B2 (en) 2006-09-25 2014-01-28 International Business Machines Corporation Providing markdown item pricing and promotion calendar
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
CA2667428A1 (en) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
KR101083177B1 (ko) 2006-10-23 2011-11-11 에스지엑스 파마슈티컬스, 인코포레이티드 트리아졸로-피리다진 단백질 키나제 조정제
GB0621607D0 (en) 2006-10-31 2006-12-06 Chroma Therapeutics Ltd Inhibitors of c-Met
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008080015A2 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
JP2010516680A (ja) 2007-01-19 2010-05-20 エックスカバリー，インコーポレイテッド キナーゼ阻害薬化合物
CL2008001540A1 (es) 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
EP2225239B1 (en) 2007-12-21 2014-10-22 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
EP2231282A1 (en) 2008-01-22 2010-09-29 Merck Patent GmbH Protein kinase inhibitors and use thereof
AU2009246263B2 (en) 2008-05-14 2014-08-21 Amgen Inc. Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer
US20110229469A1 (en) 2008-10-01 2011-09-22 Ludwig Institute For Cancer Research Methods for the treatment of cancer
WO2010059771A1 (en) 2008-11-20 2010-05-27 Osi Pharmaceuticals, Inc. Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
TW201036973A (en) 2009-03-11 2010-10-16 Plexxikon Inc Compounds and uses thereof
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa

Also Published As

Publication number Publication date
US8445510B2 (en) 2013-05-21
PT2569314T (pt) 2016-10-25
PH12012502102A1 (en) 2013-02-11
PL2569314T3 (pl) 2017-02-28
US20110281888A1 (en) 2011-11-17
JP2013526569A (ja) 2013-06-24
AR081039A1 (es) 2012-05-30
SG184822A1 (en) 2012-12-28
CA2790847A1 (en) 2011-11-17
CN102971316A (zh) 2013-03-13
ES2604481T3 (es) 2017-03-07
AU2011252784A1 (en) 2012-09-13
JP5820472B2 (ja) 2015-11-24
KR20130118213A (ko) 2013-10-29
WO2011143645A1 (en) 2011-11-17
EA201291246A1 (ru) 2013-04-30
EP2569314A1 (en) 2013-03-20
TW201141863A (en) 2011-12-01
EP2569314B1 (en) 2016-09-07
ZA201208489B (en) 2013-09-25
US20130253197A1 (en) 2013-09-26
BR112012028674A2 (pt) 2016-08-16

Similar Documents

Publication Publication Date Title
CY1122601T1 (el) Αναστολεις gsk3 και μεθοδοι χρησης αυτων
PH12012502102A1 (en) Fused bicyclic kinase inhibitors
CY1121625T1 (el) Αναστολεις prmt5 και χρησεις αυτων
CU20110027A7 (es) Peptidomiméticos de smac útiles como inhibidores de proteínas de apoptosis (iap)
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
CY1120258T1 (el) Ενωσεις ετεροδικυκλο-υποκατεστημενης-[1,2,4]τριαζολο [1,5-c]κιναζολιν-5-αμινης καταλληλες για αγωγη ή προληψη διαταραχων του κεντρικου νευρικου συστηματος
CR20120460A (es) Compuestos de sililo tricíclicos fusionados y métodos de uso de los mismos para el tratamiento de enfermedades virales
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
UY38712A (es) Lactamas fusionadas de arilo y heteroarilo
DOP2014000058A (es) 3- pirmidin- 4- il- oxazolidin- 2- onas como inhibidores de la idh mutante
CU24335B1 (es) Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
BR112012029647A2 (pt) novos derivados de pirimidinas
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
PH12015500376B1 (en) Novel bicyclic pyridinones
GB201209587D0 (en) Therapeutic compounds
GT201400100A (es) Formulaciones farmacéuticas
MX390264B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
EA201591024A1 (ru) Димерные соединения
SV2009003389A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
CO6321280A2 (es) Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
EA201391206A1 (ru) Способы синтеза производных предшественника молибдоптерина z
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.

Legal Events

Date Code Title Description
FG Grant or registration